NCT01455688

Early Antiviral Therapy for Critically Ill HIV Infected Patients

Early Antiretroviral Therapy for Critically Ill HIV Infected Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 115 (actual)
• Sponsor: Hospital Nossa Senhora da Conceicao · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to verify the effect of HAART in critically ill HIV infected patients. The current practice is to begin antiviral therapy after ICU discharge, when the condition of the patient is more stable. The investigators hypothesis is that the investigators can improve outcome of these patients with earlier antiviral therapy in the ICU. The investigators just have retrospective studies in this scenario. After admission to ICU, patients are assigned to one of two arms: early HAART (within 5 days of ICU admission) or conventional therapy (initiation of HAART after ICU discharge). The following data will be collected: demographic variables, CD4 count, viral load, drug toxicity, opportunistic infection, hemodialysis, mechanical ventilation and vasoactive drug. The patients will be followed to determine ICU mortality, hospital mortality and 6-month mortality.

Conditions

• HIV Infection

Interventions

Type	Name	Description
DRUG	early HAART	Initiation of HAART within 5 days of ICU admission
DRUG	Late HAART	Initiation of HAART after ICU discharge

Timeline

• Start date: 2012-01-01
• Primary completion: 2015-12-31
• Completion: 2016-06-30
• First posted: 2011-10-20
• Last updated: 2018-04-12

Locations

1 site across 1 country: Brazil